A recent Paul Hastings memo discusses spin-offs as a potential alternative for biotech companies to unlock value. While the memo focuses on that industry, much of its discussion of the key legal and business considerations associated with a spin-off applies to companies in any industry considering such a transaction.  This excerpt addresses some of the issues that […]